Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (8): 707-712.DOI: 10.3969/j.issn.1673-8640.2023.08.001
WANG Wei, ZHANG Zhixin, ZHANG Chuanbao, ZHOU Weiyan, WANG Zhiguo()
Received:
2023-02-10
Revised:
2023-04-14
Online:
2023-08-30
Published:
2023-10-30
CLC Number:
WANG Wei, ZHANG Zhixin, ZHANG Chuanbao, ZHOU Weiyan, WANG Zhiguo. Establishment of allowable total error,allowable imprecision and allowable bias for 22 endocrine analytes[J]. Laboratory Medicine, 2023, 38(8): 707-712.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.08.001
水平 | 允许CV | 允许Bias | TEa |
---|---|---|---|
最低水平 | CVA≤0.75CVI | BA≤0.375(CVI2+CVG2)1/2 | TEa≤1.65×(0.75CVI )+0.375×(CVI2+CVG2)1/2 |
适当水平 | CVA≤0.50CVI | BA≤0.250(CVI2+CVG2)1/2 | TEa≤1.65×(0.50CVI)+0.250×(CVI2+CVG2)1/2 |
最佳水平 | CVA≤0.25CVI | BA≤0.125(CVI2+CVG2)1/2 | TEa≤1.65×(0.25CVI )+0.125×(CVI2+CVG2)1/2 |
水平 | 允许CV | 允许Bias | TEa |
---|---|---|---|
最低水平 | CVA≤0.75CVI | BA≤0.375(CVI2+CVG2)1/2 | TEa≤1.65×(0.75CVI )+0.375×(CVI2+CVG2)1/2 |
适当水平 | CVA≤0.50CVI | BA≤0.250(CVI2+CVG2)1/2 | TEa≤1.65×(0.50CVI)+0.250×(CVI2+CVG2)1/2 |
最佳水平 | CVA≤0.25CVI | BA≤0.125(CVI2+CVG2)1/2 | TEa≤1.65×(0.25CVI )+0.125×(CVI2+CVG2)1/2 |
项目 | 2020年 | 2021年 | 2022年 |
---|---|---|---|
促甲状腺激素 | 3 540 | 3 550 | 3 555 |
游离甲状腺素 | 3 518 | 3 524 | 3 537 |
游离三碘甲状腺原氨酸 | 3 511 | 3 518 | 3 529 |
孕酮 | 3 162 | 3 161 | 3 183 |
雌二醇 | 3 058 | 3 059 | 3 073 |
睾酮 | 3 052 | 3 044 | 3 063 |
卵泡刺激素 | 3 036 | 3 029 | 3 050 |
催乳素 | 3 032 | 3 030 | 3 046 |
黄体生成素 | 3 032 | 3 024 | 3 045 |
总甲状腺素 | 2 917 | 2 924 | 2 940 |
总三碘甲状腺原氨酸 | 2 917 | 2 924 | 2 938 |
胰岛素 | 2 410 | 2 413 | 2 433 |
C-肽 | 2 158 | 2 164 | 2 177 |
叶酸 | 1 593 | 1 593 | 1 608 |
维生素B12 | 1 583 | 1 586 | 1 597 |
甲状旁腺激素 | 1 383 | 1 409 | 1 418 |
皮质醇 | 1 209 | 1 223 | 1 235 |
甲状腺球蛋白 | 1 178 | 1 187 | 1 205 |
促肾上腺皮质激素 | 725 | 739 | 751 |
生长激素 | 693 | 704 | 710 |
醛固酮 | 573 | 584 | 593 |
硫酸脱氢表雄酮 | 291 | 298 | 306 |
项目 | 2020年 | 2021年 | 2022年 |
---|---|---|---|
促甲状腺激素 | 3 540 | 3 550 | 3 555 |
游离甲状腺素 | 3 518 | 3 524 | 3 537 |
游离三碘甲状腺原氨酸 | 3 511 | 3 518 | 3 529 |
孕酮 | 3 162 | 3 161 | 3 183 |
雌二醇 | 3 058 | 3 059 | 3 073 |
睾酮 | 3 052 | 3 044 | 3 063 |
卵泡刺激素 | 3 036 | 3 029 | 3 050 |
催乳素 | 3 032 | 3 030 | 3 046 |
黄体生成素 | 3 032 | 3 024 | 3 045 |
总甲状腺素 | 2 917 | 2 924 | 2 940 |
总三碘甲状腺原氨酸 | 2 917 | 2 924 | 2 938 |
胰岛素 | 2 410 | 2 413 | 2 433 |
C-肽 | 2 158 | 2 164 | 2 177 |
叶酸 | 1 593 | 1 593 | 1 608 |
维生素B12 | 1 583 | 1 586 | 1 597 |
甲状旁腺激素 | 1 383 | 1 409 | 1 418 |
皮质醇 | 1 209 | 1 223 | 1 235 |
甲状腺球蛋白 | 1 178 | 1 187 | 1 205 |
促肾上腺皮质激素 | 725 | 739 | 751 |
生长激素 | 693 | 704 | 710 |
醛固酮 | 573 | 584 | 593 |
硫酸脱氢表雄酮 | 291 | 298 | 306 |
检验项目 | CVI① | CVG② | 最佳水平 | 适当水平 | 最低水平 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
允许CV | 允许Bias | TEa | 允许CV | 允许Bias | TEa | 允许CV | 允许Bias | TEa | |||||
游离三碘甲状腺原氨酸 | 5.0 | 8.3 | 1.3 | 1.2 | 3.3 | 2.5 | 2.4 | 6.5 | 3.8 | 3.6 | 9.8 | ||
总三碘甲状腺原氨酸 | 9.4 | 12.2 | 2.4 | 1.9 | 5.8 | 4.7 | 3.9 | 11.6 | 7.1 | 5.8 | 17.4 | ||
游离甲状腺素 | 4.9 | 7.8 | 1.2 | 1.2 | 3.2 | 2.5 | 2.3 | 6.3 | 3.7 | 3.5 | 9.5 | ||
总甲状腺素 | 6.4 | 11.8 | 1.6 | 1.7 | 4.3 | 3.2 | 3.4 | 8.6 | 4.8 | 5.0 | 13.0 | ||
促甲状腺激素 | 17.7 | 35.9 | 4.4 | 5.0 | 12.3 | 8.9 | 10.0 | 24.6 | 13.3 | 15.0 | 36.9 | ||
皮质醇 | 16.3 | 48.7 | 4.1 | 6.4 | 13.1 | 8.2 | 12.8 | 26.3 | 12.2 | 19.3 | 39.4 | ||
雌二醇 | 15.0 | 13.0 | 3.8 | 2.5 | 8.7 | 7.5 | 5.0 | 17.3 | 11.3 | 7.4 | 26.0 | ||
卵泡刺激素 | 12.4 | 42.1 | 3.1 | 5.5 | 10.6 | 6.2 | 11.0 | 21.2 | 9.3 | 16.5 | 31.8 | ||
黄体生成素 | 22.8 | 30.8 | 5.7 | 4.8 | 14.2 | 11.4 | 9.6 | 28.4 | 17.1 | 14.4 | 42.6 | ||
孕酮 | 18.5 | 39.7 | 4.6 | 5.5 | 13.1 | 9.3 | 10.9 | 26.2 | 13.9 | 16.4 | 39.3 | ||
催乳素 | 29.5 | 43.0 | 7.4 | 6.5 | 18.7 | 14.8 | 13.0 | 37.4 | 22.1 | 19.6 | 56.1 | ||
睾酮 | 12.5 | 21.4 | 3.1 | 3.1 | 8.3 | 6.3 | 6.2 | 16.5 | 9.4 | 9.3 | 24.8 | ||
C-肽 | 16.6 | 23.2 | 4.2 | 3.6 | 10.4 | 8.3 | 7.1 | 20.8 | 12.5 | 10.7 | 31.2 | ||
叶酸 | 11.8 | 37.9 | 3.0 | 5.0 | 9.8 | 5.9 | 9.9 | 19.7 | 8.9 | 14.9 | 29.5 | ||
胰岛素 | 25.4 | 33.5 | 6.4 | 5.3 | 15.7 | 12.7 | 10.5 | 31.5 | 19.1 | 15.8 | 47.2 | ||
甲状腺球蛋白 | 10.6 | 77.2 | 2.7 | 9.7 | 14.1 | 5.3 | 19.5 | 28.2 | 8.0 | 29.2 | 42.3 | ||
甲状旁腺激素 | 15.7 | 23.5 | 3.9 | 3.5 | 10.0 | 7.9 | 7.1 | 20.0 | 11.8 | 10.6 | 30.0 | ||
醛固酮 | 36.6 | 34.7 | 9.2 | 6.3 | 21.4 | 18.3 | 12.6 | 42.8 | 27.5 | 18.9 | 64.2 | ||
硫酸脱氢表雄酮 | 6.0 | 21.0 | 1.5 | 2.7 | 5.2 | 3.0 | 5.5 | 10.4 | 4.5 | 8.2 | 15.6 |
检验项目 | CVI① | CVG② | 最佳水平 | 适当水平 | 最低水平 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
允许CV | 允许Bias | TEa | 允许CV | 允许Bias | TEa | 允许CV | 允许Bias | TEa | |||||
游离三碘甲状腺原氨酸 | 5.0 | 8.3 | 1.3 | 1.2 | 3.3 | 2.5 | 2.4 | 6.5 | 3.8 | 3.6 | 9.8 | ||
总三碘甲状腺原氨酸 | 9.4 | 12.2 | 2.4 | 1.9 | 5.8 | 4.7 | 3.9 | 11.6 | 7.1 | 5.8 | 17.4 | ||
游离甲状腺素 | 4.9 | 7.8 | 1.2 | 1.2 | 3.2 | 2.5 | 2.3 | 6.3 | 3.7 | 3.5 | 9.5 | ||
总甲状腺素 | 6.4 | 11.8 | 1.6 | 1.7 | 4.3 | 3.2 | 3.4 | 8.6 | 4.8 | 5.0 | 13.0 | ||
促甲状腺激素 | 17.7 | 35.9 | 4.4 | 5.0 | 12.3 | 8.9 | 10.0 | 24.6 | 13.3 | 15.0 | 36.9 | ||
皮质醇 | 16.3 | 48.7 | 4.1 | 6.4 | 13.1 | 8.2 | 12.8 | 26.3 | 12.2 | 19.3 | 39.4 | ||
雌二醇 | 15.0 | 13.0 | 3.8 | 2.5 | 8.7 | 7.5 | 5.0 | 17.3 | 11.3 | 7.4 | 26.0 | ||
卵泡刺激素 | 12.4 | 42.1 | 3.1 | 5.5 | 10.6 | 6.2 | 11.0 | 21.2 | 9.3 | 16.5 | 31.8 | ||
黄体生成素 | 22.8 | 30.8 | 5.7 | 4.8 | 14.2 | 11.4 | 9.6 | 28.4 | 17.1 | 14.4 | 42.6 | ||
孕酮 | 18.5 | 39.7 | 4.6 | 5.5 | 13.1 | 9.3 | 10.9 | 26.2 | 13.9 | 16.4 | 39.3 | ||
催乳素 | 29.5 | 43.0 | 7.4 | 6.5 | 18.7 | 14.8 | 13.0 | 37.4 | 22.1 | 19.6 | 56.1 | ||
睾酮 | 12.5 | 21.4 | 3.1 | 3.1 | 8.3 | 6.3 | 6.2 | 16.5 | 9.4 | 9.3 | 24.8 | ||
C-肽 | 16.6 | 23.2 | 4.2 | 3.6 | 10.4 | 8.3 | 7.1 | 20.8 | 12.5 | 10.7 | 31.2 | ||
叶酸 | 11.8 | 37.9 | 3.0 | 5.0 | 9.8 | 5.9 | 9.9 | 19.7 | 8.9 | 14.9 | 29.5 | ||
胰岛素 | 25.4 | 33.5 | 6.4 | 5.3 | 15.7 | 12.7 | 10.5 | 31.5 | 19.1 | 15.8 | 47.2 | ||
甲状腺球蛋白 | 10.6 | 77.2 | 2.7 | 9.7 | 14.1 | 5.3 | 19.5 | 28.2 | 8.0 | 29.2 | 42.3 | ||
甲状旁腺激素 | 15.7 | 23.5 | 3.9 | 3.5 | 10.0 | 7.9 | 7.1 | 20.0 | 11.8 | 10.6 | 30.0 | ||
醛固酮 | 36.6 | 34.7 | 9.2 | 6.3 | 21.4 | 18.3 | 12.6 | 42.8 | 27.5 | 18.9 | 64.2 | ||
硫酸脱氢表雄酮 | 6.0 | 21.0 | 1.5 | 2.7 | 5.2 | 3.0 | 5.5 | 10.4 | 4.5 | 8.2 | 15.6 |
检验项目 | 百分差值通过率 | 当月在控CV通过率 | |||||
---|---|---|---|---|---|---|---|
最佳水平 | 适当水平 | 最低水平 | 最佳水平 | 适当水平 | 最低水平 | ||
游离三碘甲状腺原氨酸 | 58.9 | 83.1 | 92.9 | 3.6 | 24.1 | 48.9 | |
总三碘甲状腺原氨酸 | 72.9 | 92.8 | 97.3 | 11.7 | 54.2 | 84.6 | |
游离甲状腺素 | 55.8 | 81.0 | 90.8 | 1.6 | 12.4 | 41.8 | |
总甲状腺素 | 67.1 | 88.8 | 95.9 | 3.1 | 26.9 | 58.9 | |
促甲状腺激素 | 96.5 | 99.0 | 99.4 | 67.6 | 96.4 | 99.3 | |
皮质醇 | 93.5 | 98.2 | 98.8 | 37.9 | 88.6 | 98.0 | |
雌二醇 | 88.9 | 97.1 | 98.2 | 45.4 | 85.0 | 97.3 | |
卵泡刺激素 | 93.4 | 98.8 | 99.5 | 35.1 | 80.4 | 95.6 | |
黄体生成素 | 97.2 | 99.2 | 99.6 | 77.4 | 98.6 | 99.7 | |
孕酮 | 94.3 | 97.8 | 98.4 | 46.3 | 91.9 | 97.8 | |
催乳素 | 97.6 | 98.7 | 98.9 | 92.4 | 99.6 | 99.8 | |
睾酮 | 86.2 | 96.7 | 97.9 | 28.0 | 81.1 | 94.1 | |
C-肽 | 89.0 | 96.1 | 97.5 | 57.9 | 92.7 | 98.4 | |
叶酸 | 85.6 | 95.5 | 96.9 | 9.5 | 58.9 | 86.9 | |
胰岛素 | 95.9 | 97.9 | 98.2 | 85.2 | 98.7 | 99.8 | |
甲状腺球蛋白 | 94.7 | 97.8 | 98.4 | 23.8 | 70.6 | 89.5 | |
甲状旁腺激素 | 82.5 | 92.9 | 94.6 | 41.8 | 87.8 | 97.7 | |
醛固酮 | 94.5 | 96.9 | 98.6 | 81.0 | 98.6 | 100.0 | |
硫酸脱氢表雄酮 | 63.4 | 86.1 | 92.9 | 0.0 | 17.2 | 43.0 |
检验项目 | 百分差值通过率 | 当月在控CV通过率 | |||||
---|---|---|---|---|---|---|---|
最佳水平 | 适当水平 | 最低水平 | 最佳水平 | 适当水平 | 最低水平 | ||
游离三碘甲状腺原氨酸 | 58.9 | 83.1 | 92.9 | 3.6 | 24.1 | 48.9 | |
总三碘甲状腺原氨酸 | 72.9 | 92.8 | 97.3 | 11.7 | 54.2 | 84.6 | |
游离甲状腺素 | 55.8 | 81.0 | 90.8 | 1.6 | 12.4 | 41.8 | |
总甲状腺素 | 67.1 | 88.8 | 95.9 | 3.1 | 26.9 | 58.9 | |
促甲状腺激素 | 96.5 | 99.0 | 99.4 | 67.6 | 96.4 | 99.3 | |
皮质醇 | 93.5 | 98.2 | 98.8 | 37.9 | 88.6 | 98.0 | |
雌二醇 | 88.9 | 97.1 | 98.2 | 45.4 | 85.0 | 97.3 | |
卵泡刺激素 | 93.4 | 98.8 | 99.5 | 35.1 | 80.4 | 95.6 | |
黄体生成素 | 97.2 | 99.2 | 99.6 | 77.4 | 98.6 | 99.7 | |
孕酮 | 94.3 | 97.8 | 98.4 | 46.3 | 91.9 | 97.8 | |
催乳素 | 97.6 | 98.7 | 98.9 | 92.4 | 99.6 | 99.8 | |
睾酮 | 86.2 | 96.7 | 97.9 | 28.0 | 81.1 | 94.1 | |
C-肽 | 89.0 | 96.1 | 97.5 | 57.9 | 92.7 | 98.4 | |
叶酸 | 85.6 | 95.5 | 96.9 | 9.5 | 58.9 | 86.9 | |
胰岛素 | 95.9 | 97.9 | 98.2 | 85.2 | 98.7 | 99.8 | |
甲状腺球蛋白 | 94.7 | 97.8 | 98.4 | 23.8 | 70.6 | 89.5 | |
甲状旁腺激素 | 82.5 | 92.9 | 94.6 | 41.8 | 87.8 | 97.7 | |
醛固酮 | 94.5 | 96.9 | 98.6 | 81.0 | 98.6 | 100.0 | |
硫酸脱氢表雄酮 | 63.4 | 86.1 | 92.9 | 0.0 | 17.2 | 43.0 |
检验项目 | TEa | 允许CV | 允许Bias |
---|---|---|---|
游离三碘甲状腺原氨酸 | 18.9① | 6.5① | 8.2 |
总三碘甲状腺原氨酸 | 17.4② | 7.1② | 5.7 |
游离甲状腺素 | 25.0③ | 6.2① | 14.8 |
总甲状腺素 | 20.0③ | 7.0① | 8.5 |
促甲状腺激素 | 24.6④ | 8.9④ | 9.9 |
皮质醇 | 26.3④ | 8.2④ | 12.8 |
雌二醇 | 26.0② | 7.5④ | 13.6 |
卵泡刺激素 | 21.2④ | 6.2④ | 11.0 |
黄体生成素 | 25.0③ | 6.8① | 13.8 |
孕酮 | 26.2④ | 9.3④ | 10.9 |
催乳素 | 18.7⑤ | 7.4⑤ | 6.5 |
睾酮 | 16.5④ | 6.3④ | 6.1 |
C-肽 | 20.8④ | 8.3④ | 7.1 |
叶酸 | 29.5② | 8.9② | 14.8 |
胰岛素 | 25.0③ | 6.4⑤ | 14.4 |
甲状腺球蛋白 | 28.2④ | 8.0② | 15.0 |
甲状旁腺激素 | 30.0② | 11.8② | 10.5 |
醛固酮 | 21.4⑤ | 9.2⑤ | 6.2 |
硫酸脱氢表雄酮 | 25.0③ | 7.5① | 12.6 |
维生素B12 | 25.0③ | 7.5① | 12.6 |
生长激素 | 25.0③ | 7.0① | 13.5 |
促肾上腺皮质激素 | 27.4① | 9.1① | 12.4 |
检验项目 | TEa | 允许CV | 允许Bias |
---|---|---|---|
游离三碘甲状腺原氨酸 | 18.9① | 6.5① | 8.2 |
总三碘甲状腺原氨酸 | 17.4② | 7.1② | 5.7 |
游离甲状腺素 | 25.0③ | 6.2① | 14.8 |
总甲状腺素 | 20.0③ | 7.0① | 8.5 |
促甲状腺激素 | 24.6④ | 8.9④ | 9.9 |
皮质醇 | 26.3④ | 8.2④ | 12.8 |
雌二醇 | 26.0② | 7.5④ | 13.6 |
卵泡刺激素 | 21.2④ | 6.2④ | 11.0 |
黄体生成素 | 25.0③ | 6.8① | 13.8 |
孕酮 | 26.2④ | 9.3④ | 10.9 |
催乳素 | 18.7⑤ | 7.4⑤ | 6.5 |
睾酮 | 16.5④ | 6.3④ | 6.1 |
C-肽 | 20.8④ | 8.3④ | 7.1 |
叶酸 | 29.5② | 8.9② | 14.8 |
胰岛素 | 25.0③ | 6.4⑤ | 14.4 |
甲状腺球蛋白 | 28.2④ | 8.0② | 15.0 |
甲状旁腺激素 | 30.0② | 11.8② | 10.5 |
醛固酮 | 21.4⑤ | 9.2⑤ | 6.2 |
硫酸脱氢表雄酮 | 25.0③ | 7.5① | 12.6 |
维生素B12 | 25.0③ | 7.5① | 12.6 |
生长激素 | 25.0③ | 7.0① | 13.5 |
促肾上腺皮质激素 | 27.4① | 9.1① | 12.4 |
检验项目 | P90 | P10 | TEa当前 | TEa调整后① |
---|---|---|---|---|
游离三碘甲状腺原氨酸 | 16.8 | -21.0 | 18.9 | 未调整 |
游离甲状腺素 | 8.5 | -7.1 | 7.8 | 25.0 |
总甲状腺素 | 13.3 | -11.3 | 12.3 | 20.0 |
黄体生成素 | 7.4 | -7.4 | 7.4 | 25.0 |
胰岛素 | 8.0 | -7.0 | 7.5 | 25.0 |
硫酸脱氢表雄酮 | 12.6 | -9.1 | 10.8 | 25.0 |
维生素B12 | 10.0 | -10.0 | 10.0 | 25.0 |
生长激素 | 8.3 | -9.5 | 8.9 | 25.0 |
促肾上腺皮质激素 | 33.3 | -21.4 | 27.4 | 未调整 |
检验项目 | P90 | P10 | TEa当前 | TEa调整后① |
---|---|---|---|---|
游离三碘甲状腺原氨酸 | 16.8 | -21.0 | 18.9 | 未调整 |
游离甲状腺素 | 8.5 | -7.1 | 7.8 | 25.0 |
总甲状腺素 | 13.3 | -11.3 | 12.3 | 20.0 |
黄体生成素 | 7.4 | -7.4 | 7.4 | 25.0 |
胰岛素 | 8.0 | -7.0 | 7.5 | 25.0 |
硫酸脱氢表雄酮 | 12.6 | -9.1 | 10.8 | 25.0 |
维生素B12 | 10.0 | -10.0 | 10.0 | 25.0 |
生长激素 | 8.3 | -9.5 | 8.9 | 25.0 |
促肾上腺皮质激素 | 33.3 | -21.4 | 27.4 | 未调整 |
[1] |
FRASER C G. The 1999 Stockholm Consensus Conference on quality specifications in laboratory medicine[J]. Clin Chem Lab Med, 2015, 53(6):837-840.
DOI PMID |
[2] |
PANTEGHINI M, SANDBERG S. Defining analytical performance specifications 15 years after the Stockholm conference[J]. Clin Chem Lab Med, 2015, 53(6):829-832.
DOI PMID |
[3] | SANDBERG S, FRASER C G, HORVATH A R, et al. Defining analytical performance specifications:consensus statement from the 1st strategic conference of the European federation of clinical chemistry and laboratory medicine[J]. Clin Chem Lab Med, 2015, 53(6):833-835. |
[4] |
CERIOTTI F, FERNANDEZ-CALLE P, KLEE G G, et al. Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference[J]. Clin Chem Lab Med, 2017, 55(2):189-194.
DOI PMID |
[5] | JONES G R D, ALBAREDE S, KESSELER D, et al. Analytical performance specifications for external quality assessment-definitions and descriptions[J]. Clin Chem Lab Med, 2017, 55(7):949-955. |
[6] | 中华人民共和国卫生部. WS/T 403—2012 临床生物化学检验常规项目分析质量指标[S]. 北京: 中国标准出版社, 2012. |
[7] | 杜雨轩, 张诗诗, 张传宝, 等. 我国心肌标志物检验项目性能规范的设定[J]. 临床检验杂志, 2021, 39(1):47-52. |
[8] | 张诗诗, 王薇, 赵海建, 等. 临床化学检验中精密度、正确度、总误差和测量不确定度的讨论[J]. 临床检验杂志, 2017, 35(9):641-643. |
[9] | EFLM biological variation database[EB/OL]. https://biologicalvariation.eu. |
[10] | 王治国. 临床检验生物学变异与参考区间[M]. 北京: 人民卫生出版社, 2012. |
[11] | KALLNER A. Is the combination of trueness and precision in one expression meaningful?On the use of total error and uncertainty in clinical chemistry[J]. Clin Chem Lab Med, 2016, 54(8):1291-1297. |
[12] | 国家卫生健康委临床检验中心. 2022年临床检验室间质量评价计划书[EB/OL].(2021-05-30)[2022-11-12]. https://www.nccl.org.cn/showEqaPtDetail?id=1766. |
[13] | 中国合格评定国家认可委员会. CNAS-GL002:2018 能力验证结果的统计处理和能力评价指南[S]. 北京: 中国合格评定国家认可委员会, 2020. |
[14] | The Royal College of Pathologists of Australasia Quality Assurance ProgramsRCPAQAP. Chemical pathology analytical performance specifications[S]. 2021. |
[15] |
SONG Z, ZHANG J, LIU B, et al. Practical application of European biological variation combined with Westgard sigma rules in internal quality control[J]. Clin Chem Lab Med, 2022, 60(11):1729-1735.
DOI PMID |
[1] | WANG Zhengquan, WU Zhengmu, LI Wen. Long-term biological variation of serum sex hormones during female follicular phase in Shanghai [J]. Laboratory Medicine, 2024, 39(3): 282-288. |
[2] | MIAO Yingbo, ZHAO Qiang, SONG Ying, ZHU Peichao, ZHOU Wei, XU Chong. Research on performance specification of thrombelastogram [J]. Laboratory Medicine, 2022, 37(7): 680-683. |
[3] | YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348. |
[4] | LÜ Xianmin, YU Guoqi, CHEN Zhengzheng, JIANG Lihua, YAN Luwei, FEI Xianming. Consistency of abnormal results before and after re-determinations based on K+,Na+ and total calcium determinations [J]. Laboratory Medicine, 2021, 36(8): 843-846. |
[5] | MIAO Yingbo, SONG Ying, ZHAO Qiang, ZHU Peichao, ZHOU Wei, WANG Qing, XU Chong. Performance specification for differential blood count project in Shanghai [J]. Laboratory Medicine, 2021, 36(12): 1274-1276. |
[6] | LIU Huiling, WANG Bing, ZHANG Ying, ZHU Jiawen, OUYANG Qinghui. Differences of sigma performance evaluation by using allowable total errors and biases from different sources [J]. Laboratory Medicine, 2019, 34(7): 648-650. |
[7] | LIU Wenbin, JU Yi, TANG Liping, WANG Meijuan, OU Yuanzhu, YU Xiaoxuan, LI Qing. IFCC Secondary Reference Measurement Procedure for 4 HbA1c determination systems [J]. Laboratory Medicine, 2019, 34(5): 443-446. |
[8] | WU Jun, LU Renquan, GUO Lin. Role of serum CgA determination for neuroendocrine neoplasma [J]. Laboratory Medicine, 2019, 34(2): 122-125. |
[9] | ZHANG Li, HE Yao. Comparative study on reference change values and reference change factors of tumor markers [J]. Laboratory Medicine, 2019, 34(11): 991-993. |
[10] | HU Yuyi, WU Hui, HAN Xu, ZHANG Chunyan, GUO Wei, LOU Wenhui, PAN Baishen. Performance of double-antibody sandwich ELISA for chromogranin A determination [J]. Laboratory Medicine, 2018, 33(1): 55-59. |
[11] | FENG Renfeng. Role of sigma validation for the analysis performance of determination systems among clinical laboratories [J]. Laboratory Medicine, 2017, 32(10): 837-843. |
[12] | FENG Renfeng. Consensus on the analysis quality goal of clinical laboratories(Ⅱ) [J]. Laboratory Medicine, 2016, 31(2): 83-86. |
[13] | FENG Renfeng. Consensus on the analysis quality goal of clinical laboratories(Ⅰ) [J]. Laboratory Medicine, 2016, 31(1): 1-8. |
[14] | ZHANG Lu, WANG Wei, WANG Zhiguo. Application of allowable total error in sigma metrics for assessing the analytical quality of clinical chemistry determination [J]. Laboratory Medicine, 2015, 30(9): 953-957. |
[15] | CHEN Hongyan, QIU Haiwen. Investigation on the establishment of reference change values for test results [J]. Laboratory Medicine, 2015, 30(5): 529-532. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||